IPA

company builds on earlier glp-1 success with breakthrough ai-led insights into aging biology -- targeting the widely projected $60b longevity therapeutics market hyft®-driven discovery supports co-administration of mindwalk’s proprietary companion therapeutic with the company’s glp-1 receptor agonist austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company, today announced a major advancement of its ai-designed glp-1 therapeutics program. new insights from the company’s lensai™ platform reveal a previously unrecognized connection between glp-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. the findings support a first-in-class dual-pathway regimen in which mindwalk’s proprietary companion therapeutic is co-administered with its glp-1 receptor agonists (glp-1ras) to engage both mechanisms in concert. to the company’s knowledge, no approved or marketed drugs use this regimen. the companion therapeutic is a mindwalk-exclusive asset and is not a repurposed or co-branded product. this strategic evolution builds directly on mindwalk’s earlier success designing glp-1ras entirely in silico and positions the company to address the high-growth longevity therapeutics market, widely projected to exceed $60 billion by 2030. key takeaways expansion builds directly on mindwalk’s previously announced glp-1ra success. lensai™ identifies a complementary longevity-linked pathway and guides a proprietary companion therapeutic designed to be administered alongside mindwalk’s glp-1ras. regimen is first-in-class to the company’s knowledge and engineered for preventive, chronic use. strategy aims to enhance efficacy, durability, and long-term adherence. platform enables repeatable, in silico design and optimization of combination therapeutics in high-growth markets. redefining the scope of glp-1 therapeutics with bio-native ai using hyft®, mindwalk’s patented first-principles discovery engine, lensai™ mapped conserved biological patterns that link glp-1 signaling to adaptive resilience in metabolism, inflammation balance, and cellular stress response. in parallel, lensai™ identified a complementary regulatory node—kept undisclosed while validation and protection activities proceed—that interfaces with these same longevity-relevant processes. together, these insights form the basis of a novel dual-pathway regimen designed to maintain the benefits of glp-1 while broadening impact on healthspan outcomes. unlike traditional black-box ai tools, lensai™ provides explainability, biological traceability, and full lineage tracking designed to support regulatory review of ai-informed decisions throughout discovery and development. “glp-1 drugs have already transformed diabetes and obesity care, but their potential as healthspan medicines is only beginning to be recognized,” said dr. jennifer bath, ceo of mindwalk. “by applying hyft® and lensai™, we are not simply iterating on existing drugs—we are uncovering first principles that enable the design of safe, durable glp-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway. to our knowledge, this represents a new route in longevity medicine and a direct evolution of our earlier success, showing how our bio-native ai platform creates repeatable, high-impact programs in preventive health.” scientific foundation: a confidential, complementary longevity pathway leveraging mindwalk’s patented hyft® patterns—universal biological fingerprints that encode conserved sequence-structure-function relationships—lensai™ integrated sequence models, structural predictions, and knowledge-graph reasoning to highlight a second, non-overlapping pathway that operates alongside glp-1 in maintaining cellular robustness. while specific target details remain undisclosed, this hyft-anchored analysis indicates that coordinated engagement of both mechanisms may help sustain high-quality signaling, moderate stress responses, and reinforce metabolic balance over time—key aims for healthspan-oriented, chronic therapies. the regimen is engineered to sustain high-quality glp-1 signaling while engaging complementary resilience processes implicated in healthy aging. mindwalk has initiated intellectual-property protection around the companion therapeutic and regimen design. recent progress and forward strategy earlier this year, mindwalk reported that its ai-designed glp-1 peptides matched or exceeded semaglutide—a global market leader—in receptor activation assays. those sequences were discovered, selected, and optimized entirely in silico using lensai™, marking a major milestone in scalable, data-driven drug discovery. building on that foundation, the company is now advancing a dual-pathway program that includes: ai-optimized, long-acting glp-1 analogs for durable, patient-friendly dosing; a mindwalk-exclusive companion therapeutic directed at a longevity-linked, non-overlapping pathway for regimen-level co-administration; in silico exploration of dose, schedule, and sequence design to inform preclinical evaluation of the proprietary combination; incorporation of aging biomarkers and healthspan endpoints into discovery and preclinical prioritization; and mindwalk expects to provide updates on lead selection for the companion therapeutic, preclinical combination design parameters, and potential development paths for the regimen in the coming quarters. “this announcement reflects the scalability of mindwalk’s bio-native ai platform and its ability to address high-value therapeutic categories with speed and scientific rigor,” said dr. dirk van hyfte, cto of mindwalk bv. platform scalability: beyond a single mechanism the dual-pathway glp-1 program exemplifies the scalability and repeatability of mindwalk’s approach. the same hyft®-driven framework is being applied across additional therapeutic areas—including oncology, immunology, and vaccine design—enabling a multi-program pipeline built from a single, explainable ai foundation. mindwalk’s platform is used by leading biopharma partners and supports multi-program discovery across modalities. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s expansion of its glp-1 receptor agonist program toward longevity and healthspan medicine; the anticipated benefits of applying hyft® technology and the lensai™ platform to metabolic and aging biology; the development and potential of a co-administered proprietary companion therapeutic engaging a complementary longevity pathway; the potential for next-generation glp-1 therapeutics to achieve outcomes beyond glycemic control; and the scalability and repeatability of the company’s bio-native ai approach across therapeutic areas. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks inherent in drug discovery and development; challenges in validating preclinical findings in clinical settings; regulatory approval requirements and uncertainties; market adoption dynamics in longevity and metabolic medicine; competitive developments in glp-1 and adjacent therapeutic classes; intellectual property protection; reliance on third-party partners; and broader economic, geopolitical, or regulatory shifts. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

an evolution in name, structure, and strategy reflecting the company’s ai-driven platform and bio-native discovery vision austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), immunoprecise antibodies ltd. and its subsidiaries (biostrand and talem) today announced a unification under a single corporate brand, mindwalk, and a change of its nasdaq ticker symbol to hyft. the new identity conveys the company’s evolution into a bio-native ai platform business built at the intersection of ai, multi-omics data, and advanced laboratory research. “today is an evolutionary step forward,” said dr. jennifer bath, president and chief executive officer of mindwalk. “inspired by darwin’s thinking path, mindwalk is about seeing what others can’t—patterns hidden in biology that point to better medicines. our role is to convert that insight into impact, uniting science, computation, and responsible experimentation to change the pace of care.” mindwalk: a new era in bio-native ai-powered discovery inspired by charles darwin’s daily walks along his “thinking path” — where he questioned convention and advanced new theories — mindwalk carries that spirit forward. it represents a modern extension of that philosophy: a transformative, pattern-seeking journey through the complexity of biology, powered by the combined strengths of ai, data and advanced lab research. now operating as a bio-native ai company, mindwalk reimagines discovery by intelligently integrating data across formats and disciplines—turning information into dynamic biological meaning. by making biological diversity computable, mindwalk unifies this data into a single, structured system that accelerates discovery with depth and direction. at the core of this transformation is the company’s lensai™ platform powered by hyft® technology, built to redefine how biologics are discovered and developed. drug discovery, unified—from idea to impact. this brand evolution is also a business transformation. mindwalk is expanding beyond specialized wet-lab services to commercialize an intelligence-platform model—amplifying discovery, enabling recurring saas offerings, creating generative asset opportunities, and supporting scalable partnerships across the pharmaceutical ecosystem. key business highlights: unified brand identity: immunoprecise antibodies (ipa) together with its subsidiaries biostrand and talem are now unified as mindwalk, a single brand under the umbrella of mindwalk holdings corp. business model shift: transitioning from standalone wet-lab services to an integrated, scalable platform company model — launching daas, saas offerings, enhancing asset generation, and enabling large-scale partnerships new nasdaq ticker: “hyft” — replacing “ipa” to reflect the foundational role of hyft ® technology in the company’s ai stack “mindwalk is the first to make biological diversity truly computable — integrating multi-modal data into a structured system that drives insight with clarity, speed, and depth,” added dr. bath. for more information visit: mindwalkai.com about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s name change and ticker symbol transition to “hyft,” the anticipated benefits of rebranding under the mindwalk ai identity, projected scalability and adoption of the hyft® technology and lenai™ platform, and the company’s strategic shift toward a unified, ai-native discovery model. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: operational challenges in executing the rebrand and technology consolidation; risks associated with platform scalability and ai integration; scientific or technical validation hurdles; evolving market adoption dynamics in the saas and biologics r&d sectors; economic, geopolitical, or regulatory shifts; and customer or partner response to the new corporate structure. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mab) responses. austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. building on its june announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its lensai™ platform powered by patented hyft® technology, the company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralization analysis. the manufactured product will be used in proprietary immunization protocols at ipa’s canadian facility. these studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mab) responses—a crucial step toward translational development. “this is the natural next step in our journey from ai discovery to real-world validation,” said dr. jennifer bath, ceo of immunoprecise. “we’ve shown that hyft technology can identify vaccine targets that others miss — unique targets that are conserved, specific, and immunologically relevant. now we’re now moving into manufacturing and live immunization studies, where the question becomes: can this target elicit a powerful and protective antibody response? this is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases.” the science behind the step: ai discovery → manufacturing: hyft-guided analysis revealed a discontiguous dengue epitope conserved across all four virus serotypes. validated safety & immunogenicity: in silico screens confirmed immune activation potential (b- and t-cell responses), structural stability, and comprehensive safety against host proteomes. now entering immunization studies: the product is being synthesized and will be used in rabbit models to assess whether it elicits specific monoclonal antibodies — an essential proof point for vaccine development. a platform approach, not just a vaccine: this progression highlights ipa’s end-to-end advantage: combining ai-native discovery with in-house wet-lab validation. with regulators like the u.s. fda encouraging predictive, human-relevant approaches that reduce reliance on animal testing, immunoprecise’s in silico-to-in vivo workflow represents a forward-looking model for next-generation vaccine r&d. by applying the same methodology across pathogens, ipa is positioning its lensai/hyft platform as a versatile discovery engine — not only for dengue, but also for other infectious diseases and immuno-oncology targets. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutics company focused on the discovery and development of next-generation biologics. the company combines scientific expertise with proprietary technologies—such as its lensai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. ipa supports global partners in advancing novel therapeutics, diagnostics, and translational research. for more information, visit www.ipatherapeutics.com. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s advancement of its universal dengue vaccine initiative, the anticipated benefits of its proprietary hyft® and lensai™ platforms, the potential for its vaccine candidate to generate protective monoclonal antibody responses, and the broader applicability of its ai-native discovery platforms to infectious diseases and immuno-oncology. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks inherent in preclinical studies and vaccine development; uncertainties in manufacturing, immunization, and virus neutralization testing; execution risks related to ai-driven discovery and translational validation; the pace and accuracy of scientific and technological innovation; competitive dynamics in biologics and vaccine r&d; customer and partner adoption rates; and shifts in economic, market, or regulatory conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its netherlands-based subsidiary, immunoprecise antibodies (europe) b.v. (“ipa europe”), to avs bio for a total enterprise value of $12 million usd. avs bio, a portfolio company of arlington capital partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. the transaction generated $11.7 million usd in net proceeds on a cash-free, debt-free basis. this transaction marks a meaningful step in ipa’s strategic refinement—streamlining its operational footprint, strengthening its balance sheet, and allowing the company to concentrate resources on its most impactful growth areas. the proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs. “this transaction delivers strong value to ipa and our investors,” said dr. jennifer bath, president and ceo of immunoprecise antibodies ltd. “it reflects our disciplined strategy to focus resources on our ai-based software as a service (saas) platform—where we’re combining scientific expertise with advanced technologies to accelerate modern biologics discovery. we’re proud of the business we’ve built in the netherlands and confident it will continue to thrive under avs bio’s ownership.” ipa’s global operations span biologics discovery, engineering, and characterization, supported by lensai™, the company’s proprietary platform powered by hyft® multi-omics technology. lensai helps unify and interpret complex biological data, enabling more integrated insights and smarter decisions across the discovery and development process. by harmonizing data across modalities, the platform supports faster identification of opportunities and reduces inefficiencies that typically slow biologics innovation. the sale was conducted through a competitive, arm’s-length process. a 12-month transition services agreement (tsa) will provide continuity across key functions during the transition. ipa holds no material ongoing relationship with avs bio or its affiliates beyond the scope of the transaction. edgemont partners served as exclusive financial advisor to ipa. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutics company focused on the discovery and development of next-generation biologics. the company combines scientific expertise with proprietary technologies—such as its lensai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. ipa supports global partners in advancing novel therapeutics, diagnostics, and translational research. for more information, visit www.ipatherapeutics.com. about avs bio headquartered in norwich, ct, avs bio is a global provider of specific pathogen-free (spf) laboratory products and services that support the development and manufacture of vaccines, therapeutics, and biologics. the company supplies leading manufacturers with critical bioprocessing inputs including spf eggs, antigens, and antibodies, and also offers diagnostic testing and gmp support services. avs bio operates more than 20 facilities across north america and europe and is a portfolio company of arlington capital partners. for more information, visit www.avsbio.com. about arlington capital partners arlington capital partners is a washington, d.c.-area private investment firm specializing in government-regulated industries. the firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. since its inception in 1999, arlington has invested in over 175 companies and is currently investing out of its $3.8 billion fund vi. for more information, visit arlington’s website at www.arlingtoncap.com and follow arlington on linkedin. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the anticipated benefits of the divestiture of ipa europe, the company’s strategic focus on its ai-native platforms, projected scalability and market adoption of its lensai™ platform, and the impact of reinvestment into data-driven, biologics discovery technologies. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: operational challenges in transitioning the divested business; execution risks related to ai-driven platform scaling; the pace and accuracy of scientific and technological innovation; changes in competitive dynamics within saas and biologics r&d markets; customer adoption rates; and shifts in economic, market, or regulatory conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com avs bio & arlington capital partners ryan fitzgibbon pro-arlington@prosek.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a bio-native ai pioneer operating where techbio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its lensai™ immunogenicity screening can reliably predict anti-drug-antibody (ada) risk for therapeutic proteins before they enter animal studies or human trials. “ada-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,” said dr. jennifer bath, president & ceo, ipa. “with lensai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.” late‑stage ada failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑mhc ii binding across a few dozen hla alleles—leaving large swaths of immune diversity untested and immunogenic “self/non‑self” checks largely unaddressed. lensai’s hyft‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. it evaluates nearly 900 hla variants and performs a whole‑proteome “humanness” scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. by revealing design‑level fixes before expensive animal studies or repeat gmp production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. study highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ada dataset to predict immunogenicity risk single composite score tracks clinical reality – enables reliable ada incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ada in patients). the discriminative capability is very powerful as indicated by an auc=0.92. alignment-free, hyft-powered engine – the proprietary screening algorithm combines state-of-the-art mhc ii binding with ipa’s proprietary hyft® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. detailed amino acid and epitope-level immunogenicity “self” scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. read the full case study: [link] about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward looking statements within the meaning of applicable united states and canadian securities laws. forward looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. examples include statements regarding the projected performance, scalability, and market adoption of the company’s lensai™ immunogenicity screening; the ability of its hyft® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ada prediction on biopharma r&d efficiency; and the company’s broader scientific, commercial, and capital markets objectives. forward looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results could differ materially from those expressed or implied because of factors beyond the company’s control, including the pace of scientific and technological innovation in ai driven drug discovery, the accuracy and regulatory acceptance of in-silico ada risk screening, competitive shifts as the industry transitions away from ms dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a bio-native ai company operating at the intersection of techbio and next-generation drug discovery, today announced the appointment of jeff fried to its advisory board. a recognized leader in healthcare data infrastructure and ai innovation, jeff fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. he currently serves as director of platform strategy and innovations for intersystems, where he helps shape high-performance data solutions for some of the world’s most demanding healthcare and life sciences environments. he has served on advisory boards for industry, government, and academia, and served as cto for teloquent (acquired by syntellect), empirix (acquired by infovista), and ba insight (acquired by upland software), as well as product leadership roles at fast search and microsoft. mr. fried has been an enthusiastic advocate for ipa’s lensai™ platform, praising its ability to unify biological sequence, structure, function, and scientific literature into a searchable, ai-ready framework. he has played a pivotal role in supporting biostrand’s partnership with intersystems to integrate advanced vector search capabilities into lensai—helping unlock powerful new possibilities for ai-driven research, diagnostics, and therapeutic development. “we are excited to welcome jeff to our advisory board at a time when our vision for a scalable, bio-native ai infrastructure is rapidly becoming a reality,” said dr. jennifer bath, ceo of ipa. “jeff’s insights at the intersection of healthcare data architecture and ai-enabled discovery are invaluable as we continue to expand lensai’s capabilities and reach across life sciences.” “lensai is one of the most exciting ai platforms i’ve encountered in the life sciences space,” said fried. “it solves a foundational problem—making biological data interoperable and computationally accessible at scale. i’m thrilled to contribute to ipa’s vision and help shape the future of bio-native ai drug discovery.” fried’s appointment underscores ipa’s commitment to enabling discovery work at the speed of computation, not convention, by providing the bio-native ai infrastructure the life sciences industry truly needs—fast, scalable, and grounded in real biological data. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the company’s strategic direction, the company’s future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in ai and biotechnology; and other risks inherent to the company’s industry and business model. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a company operating at the convergence of techbio and biological intelligence, today announced that it has received formal notification from the nasdaq stock market llc (“nasdaq”) confirming that the company has regained compliance with nasdaq listing rule 5550(a)(2), concerning the minimum bid price requirement. the notice, dated july 11, 2025, stated that for the 10 consecutive business days from june 26, 2025, through july 10, 2025, the closing bid price of the company's common shares was at or above $1.00 per share. as a result, immunoprecise has satisfied the requirements for continued listing on the nasdaq capital market, and the matter is now closed. “this compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native ai,” said dr. jennifer bath, ceo of immunoprecise. “we’re building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. the recent momentum in our share price is a strong signal of support for that vision.” through its proprietary lensai™ platform powered by hyft® technology, immunoprecise is reimagining how biological data can be modeled and deployed at scale. the lensai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere. our integrated framework enables unprecedented zero-shot discovery scenarios where lensai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. this unique bio-native ai approach captures functional meaning rather than structural patterns, enabling new capabilities across r&d from drug and vaccine discovery to systems biology and positioning ipa at the frontier of techbio innovation. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the company’s strategic direction, the company’s future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in ai and biotechnology; and other risks inherent to the company’s industry and business model. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

new benchmark confirms lensai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), an ai-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, lensai, powered by ipa’s patented hyft® technology. the newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. “it’s generally assumed that ai can only make accurate predictions if it has seen similar data before,” said dr. jennifer bath, ceo of immunoprecise. “but this benchmark proves otherwise: lensai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. not the antibodies. not the targets. not the complexes. and the predictions aligned with wet-lab results. this is a major breakthrough in generalizing ai for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. it shows that ai doesn’t always need massive data to be powerful and accurate - it just needs the right kind.” lensai epitope mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. unlike traditional methods that take months and require lab work, lensai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. in a new benchmark study, lensai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. despite having no prior exposure to these molecules, lensai achieved prediction scores nearly identical to those from its original training data. this score, known as auc (area under the curve), is a widely accepted measure of accuracy in computational biology. the consistent performance on entirely new, unseen complexes confirms that lensai’s artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. this breakthrough demonstrates lensai’s power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. why this benchmark matters in the new study, lensai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. what it means for partners and investors with lensai already embedded in collaborations across big pharma and biotech, immunoprecise is scaling access through secure apis and custom partnerships. the platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of ai-driven antibody therapeutics. for more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of lensai epitope mapping. the first highlights performance on a “seen” target, where the system was trained on related data. the second - featured in this press release - demonstrates lensai’s breakthrough ability to accurately map binding sites on a completely “unseen” target, with no prior exposure to the antibody, the antigen, or their structure. new case study:lensai epitope mapping on an “unseen” target[ link] previous case study:head-to-head benchmark on a “seen” target[ link] these examples underscore how lensai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the lensai™ and hyft® platforms; the generalizability of the company’s ai models to novel therapeutic targets; the role of ai in accelerating antibody discovery; and the company’s future scientific, commercial, and strategic developments. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for ai-driven therapeutic platforms. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

follow-up to june 5, 2025, announcement demonstrates validated vaccine candidate with strong translational potential austin, texas--(business wire)-- immunoprecise (nasdaq: ipa), a leader in ai-driven biotherapeutics, provides a significant update following its june 5, 2025, press release immunoprecise announces ai-driven breakthrough in universal dengue vaccine discovery. this new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. “this is a major step forward,” said dr. jennifer bath, ceo of immunoprecise. “our ai technology not only found a new target for a universal dengue vaccine, but we’ve now shown it’s safe and can trigger the right immune response. with this validation, we’re excited to move ahead and advance this candidate toward the next stages of vaccine development.” following the recent discovery of a unique “achilles’ heel” shared by all four types of dengue virus, immunoprecise has confirmed—using its patented hyft technology and lensai immunogenicity screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. this breakthrough may pave the way for a safer, more universal dengue vaccine. the new target was discovered using the company’s proprietary lensai platform. “our ability to move from computational discovery to ai-guided immunogenicity validation is unique to our methodology and drug development,” commented dr. jennifer bath, immunoprecise ceo. “further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.” for decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn’t guarantee protection from the others. many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. what makes this development so important is that immunoprecise’s target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both b cells and t cells, in a manner that appears safe and highly specific. immunoprecise’s latest ai-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body’s defenses in a very precise way, without the risks of traditional, broader approaches. a methodology that changes the game—far beyond dengue what sets immunoprecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. with lensai powered by hyft technology, ipa brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. by revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design. the findings for dengue showcase the platform’s versatility. because hyft technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping ipa to tackle a wide spectrum of infectious diseases, from hiv and influenza to emerging pathogens and oncology targets. with this approach, immunoprecise isn’t just keeping pace with the field; it’s setting a new standard for how next-generation therapeutics are discovered and validated. immunoprecise's patented hyft technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (denv-1 through denv-4). this target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine. this hyft-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3d shape. this advanced mapping process combines genetic similarity analysis with 3d structural modeling and functional annotation to identify the most promising vaccine targets. key technical findings complete immune response testing computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (b cells) and infection-fighting cells (t cells) would respond to the vaccine target. the target site showed strong predicted binding to multiple human immune system markers (hla class i and ii types). this suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment. safety verification against human proteins using immunoprecise's proprietary retrieve-and-relate technology at the core of hyft™ ( van hyfte et al., 2023, biorxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. this comprehensive safety check goes beyond standard comparison methods—hyft systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. this is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. no problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells. structural stability analysis advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. stability testing demonstrated that the target remains robust under normal physiological conditions. balanced immune response profile importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. this balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ade)—a serious complication that can worsen dengue infection. looking ahead this release is the second in a series of disclosures aimed at showcasing the power of immunoprecise’s end-to-end ai-native platform. the june 5th announcement introduced a promising target; today’s release provides the crucial next step: a rigorous validation of that target’s safety and immunological relevance. this validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation. these findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. ipa is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the lensai™ and hyft® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of ai-native approaches for dengue and other infectious diseases; and the company’s ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of ai designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

breakthrough in ai-powered drug discovery validates hyft™-driven peptide design, with broad potential across multiple therapeutic areas austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa), a leader in ai-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (ai)-designed glp-1 receptor agonist (glp-1ra) peptide sequences achieve comparable or superior receptor activation to semaglutide, a benchmark glp-1 therapy and one of the most commercially successful drugs in the world. the in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. the results validate the power of ipa’s lensai™ platform and its proprietary hyft™ technology, which enables first-principles-based in silico peptide discovery and optimization. five rationally engineered peptide sequences—ai-optimized for improved stability and peptidase resistance—were tested against benchmark glp-1 analogs in receptor activation assays. two lead candidates outperformed or matched semaglutide under controlled assay conditions. crucially, the sequences were not discovered by chance. they were designed using hyft-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. with glp-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that ai can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same hyft-driven approach. “this is not a one-off success,” said dr. jennifer bath, ceo of immunoprecise. “we’ve demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. hyft-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. it represents a foundational shift in how therapeutics are discovered. the same lensai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with glp-1.” ipa is now considering two complementary preclinical paths for its lead glp-1 candidates: injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. the sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. the significance of this breakthrough extends far beyond glp-1. the same ai framework and hyft-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. this announcement follows ipa’s recent success with ai-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft™ technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the lensai™ and hyft® platforms; the advancement and regulatory acceptance of ai-native drug discovery methods; the continued development and potential preclinical or clinical progression of ipa’s ai-designed glp-1 peptide program; the feasibility of next-generation delivery strategies; and the company’s ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of ai-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

lensai™ powered by hyft® technology identifies a single multi-factorial target conserved across all dengue serotypes. austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary lensai™ platform powered by their patented hyft® technology. this discovery, made using several proprietary hyft-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. this discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the company’s newly launched, hyft pattern-patented ai-native vaccine discovery engine. dr. jennifer bath, immunoprecise antibodies ceo commented, “this breakthrough highlights a new frontier in ai-driven biology—where discovery is rooted in the biology of a virus itself. by confirming that our sequence-derived patented hyft patterns match structural signatures across all dengue serotypes, we’re setting the stage for a universal vaccine design framework. ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. more importantly, the implications appear to stretch far beyond the dengue virus. this is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.” building on this success in dengue, ipa now intends to extend its ai-driven vaccine design platform to other high-impact infectious diseases, for example, hiv, norovirus, and an improved rsv vaccine. early-stage assessments are also underway to explore the platform’s application in oncology for neoantigen vaccine development and tumor-specific epitope mapping. this discovery underscores ipa’s commitment to advancing drug discovery through innovative, human-relevant ai technologies that align with evolving industry standards. using hyft’s patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the company’s proprietary lensai platform identified a unique epitope shared across all four serotypes of the dengue virus—denv-1, denv-2, denv-3, and denv-4. these serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. unlike traditional trial-and-error methods, ipa’s discovery was achieved entirely in silico, demonstrating the platform’s power to translate complex biological data into actionable vaccine design. breaking the dengue barrier: patented hyft-powered ai achieves what decades of science could not why has a universal dengue vaccine been so elusive? dengue is not just one virus—it’s four distinct, rapidly-evolving serotypes. immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. for decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus’s rapid mutation and complex immune interactions. traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale. confirmed breakthrough: sequence and structural hyft match across all four serotypes ipa’s discovery is a landmark moment in computational vaccinology. using its proprietary lensai™ platform powered by their patented hyft® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes—a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. this achievement marks a critical milestone in the quest for a universal dengue vaccine. what sets this apart is the depth of validation: · patented hyft patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural hyfts across all four dengue serotypes. · this was made possible through lensai’s integration of over 20 million proprietary structural hyfts (s-hyfts), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints. · the validation demonstrates that lensai doesn’t simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-em. this milestone affirms the patented hyft technology’s unique ability to traverse the full biological hierarchy—from dna/rna sequence to molecular structure to therapeutic relevance. it signals that ai-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research. the end-to-end lensai platform integrates patented hyft® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. the result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. these statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the lensai™ and hyft® platforms; the advancement and regulatory acceptance of ai-native drug discovery and vaccine development methods; the expansion of ipa’s discovery engine to additional infectious disease and oncology targets; and the company’s ongoing ability to maintain scientific, regulatory, and commercial momentum. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the lensai™ platform, with a direct comparison to gold-standard wet-lab methods. the results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. lensai’s ai-powered platform was able to match the performance of x-ray crystallography—the industry’s most precise but slowest and most expensive method—using sequence data alone. "in an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn’t a luxury—it’s a necessity," said dr. jennifer bath, ceo of ipa. "with lensai, we’re demonstrating that ai is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work." in the benchmarking study, lensai’s in silico epitope mapping application was tested across five known antibody-antigen pairs and against multiple experimental techniques, including hdx-ms, alanine scanning, and x-ray crystallography. the ai system produced predictive scores (auc 0.79–0.89) comparable to or exceeding those achieved by leading wet-lab methods, while reducing turnaround time from weeks to hours. epitope mapping is a cornerstone of antibody development, informing everything from ip strategy to candidate selection. traditionally, this requires expensive, time-consuming lab work using scarce protein samples. lensai transforms this by delivering early-stage epitope insights from sequence alone, reducing both cost and risk. this breakthrough aligns with growing regulatory and industry momentum around new approach methodologies (nams), including the fda’s recent decision to phase out animal testing requirements for biologics. by eliminating the need for physical materials and enabling near–x-ray-level precision, lensai advances ethical, scalable, and high-resolution approaches to biotherapeutic discovery we view this achievement as a meaningful advancement that enhances the capabilities of drug discovery platforms" added dr. bath. "lensai is now capable of providing pharma and biotech partners with validated, in silico answers to questions that once required months of wet-lab commitment." this latest achievement marks a major step in the broader development of lensai, ipa’s ai-driven discovery platform. building on previous releases, including in silico antibody engineering, epitope prediction, and multi-omics integration, lensai continues to demonstrate its ability to deliver high-resolution, scalable insights across key stages of biotherapeutic discovery. today’s advancement in epitope mapping reflects the growing power of the platform we have been strategically building — connecting sequence-based precision, accelerated timelines, and deep scientific insight to transform the future of therapeutic development. to read the full case study: lensai epitope mapping matches x-ray crystallography about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as "expects," "intends," "anticipates," "believes," or variations thereof, or state that certain actions, events, or results "may," "will," "could," or "might" occur. these statements relate to, among other things, the anticipated benefits, scalability, and adoption of the lensai platform, the broader application of hyft®-based tools, the advancement of ai-native drug discovery methods, and the company’s ability to maintain regulatory alignment and commercial traction. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory changes and acceptance, competitive dynamics, ip protection, platform integration challenges, and financial and operational risks. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) a leader in ai-driven biotherapeutics, today announced its strong support for the u.s. food and drug administration’s (fda) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. the fda’s announcement marks a significant advancement in regulatory modernization and aligns fully with immunoprecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary ai platform, lensai™. “this policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,” said dr. jennifer bath, ceo of immunoprecise antibodies. “ipa has long championed the transition toward more ethical, efficient, and accurate methodologies. our ai-powered lensai™ platform and suite of integrated discovery tools were designed precisely to support this new era of translational science.” ipa provides validated ai-driven methodologies that directly align with the fda's shift towards new approach methodologies (nams). these advanced tools effectively address critical drug development challenges, including safety, toxicity, immunogenicity, and efficacy, by leveraging sophisticated predictive capabilities: 1. safety and toxicity prediction: ipa’s lensai platform utilizes ai analytics to accurately predict potential toxicities by mapping drug interactions across the human proteome, significantly reducing the reliance on animal models. 2. immunogenicity screening: the platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient-specific strategies. 3. knowledge graphs for drug efficacy: ipa’s semantic knowledge graphs integrate biological data and scientific literature, enabling precise predictions of drug efficacy and interactions in human systems. through transitioning from animal testing to ai-driven methodologies, ipa aims to streamline preclinical workflows, reduce development costs, uphold higher ethical standards, and support regulatory compliance in line with the fda’s nams framework. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of ipa’s ai-driven methodologies, the integration of lensai and biostrand’s platforms into drug discovery, and the potential impact of regulatory shifts on ipa’s business and product development. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

programs to be driven through patented ai technology and advanced proprietary b cell platforms partnership advances next-generation adcs and bispecific antibodies to address unmet medical needs austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of antibody-drug conjugates (adcs) and bispecific antibodies for the treatment of cancer. this collaboration focuses on leveraging contract research expertise while integrating ipa’s proprietary b-cell select™ platform and artificial intelligence-driven discovery capabilities to enhance the efficiency and precision of therapeutic development. under the terms of the agreement, the partnership will encompass the discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, with a focus on developing highly selective and effective cancer treatments. ipa’s proprietary multi-omics ai-driven modeling and discovery platform, combined with its b-cell select™ technology, will be integrated at key stages to optimize therapeutic selection and accelerate lead development. the agreement, valued at an initial $8 million with the potential to expand to $10 million based on program progression, will span 18 to 24 months, integrating artificial intelligence across the workflow to enhance discovery and optimization. this collaboration aims to streamline the path from target discovery to preclinical candidate selection, marking a significant step toward advancing next-generation biologics for cancer treatment. “this partnership underscores the power of combining ai-driven discovery with advanced antibody engineering,” said dr. jennifer bath, ceo of immunoprecise antibodies. “with the purchase order secured and work already underway, we are actively leveraging our proprietary b-cell select™ platform and lensai™ technology to accelerate the development of highly targeted cancer therapeutics. this collaboration highlights ipa’s role in shaping the future of next-generation biologics with data-driven precision and efficiency.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of the collaboration, the integration of ai-driven workflows into drug discovery, and the potential impact of the partnership on advancing adc and bispecific antibody development. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a global leader in ai-powered antibody discovery and development, today announced a strategic collaboration with ribopro, a pioneering technology provider specializing in mrna and lipid nanoparticle (lnp) technologies. this collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating ribopro’s advanced mrna-based antigen expression expertise with ipa’s in silico and wet-lab antibody discovery capabilities. the collaboration leverages ribopro’s expertise in mrna sequence optimization and lnp-based delivery with ipa’s advanced b-cell screening, single-cell analysis, and deep-learning ai-driven discovery workflows. together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery. transforming antibody discovery with mrna technology the success of generating therapeutic lead antibodies towards complex antigens using traditional immunization-based discovery platforms may be hampered by challenges associated with the proper expression of these antigens. by leveraging ribopro’s proprietary mrna and lnp technologies, this partnership enables precise, efficient antigen expression, thereby facilitating potentially more effective immune responses and possibly accelerating the path to discovering novel antibody therapeutics. “partnering with immunoprecise antibodies enables us to push the boundaries of mrna-based immunization for therapeutic antibody discovery,” said sander van asbeck, ceo of ribopro. “by integrating our expertise in mrna design and nanoparticle delivery with ipa’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen expression, bringing forth new possibilities for precision therapeutics.” driving innovation in ai-powered antibody discovery ipa’s approach combines advanced ai-driven analytics with highly specialized wet-lab methodologies to design and optimize antibodies with the highest clinical relevance. the integration of mrna immunization into ipa’s workflow is expected to further enhance the precision and efficiency of their antibody discovery pipeline. “we are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mrna immunization platform in this alliance,” said dr. ilse roodink, cso of immunoprecise antibodies. “combining ribopro’s and ipa’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.” about ribopro ribopro is a netherlands-based technology and service provider specializing in mrna and lipid nanoparticle (lnp) technologies. founded in 2020, ribopro develops and manufactures high-quality mrna and lnps while offering innovative solutions, including sequence optimization algorithms and a proprietary lnp platform. these technologies are designed to enhance immune responses, improve safety profiles, and enable targeted mrna delivery beyond the liver. ribopro provides cmo, cdmo, and cro services to biotech and pharmaceutical companies seeking next-generation solutions for mrna therapeutics. for more information, visit www.ribopro.eu media contact: silvy van tuijl, chief of staff, ribopro | info@ribopro.eu |+31 85 060 67 62 about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutic research and technology company specializing in ai-driven antibody discovery and development. through its subsidiaries—including talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v.—ipa delivers an end-to-end solution for the development of next-generation antibody therapeutics. the company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets. for more information, visit www.ipatherapeutics.com investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the collaboration between immunoprecise antibodies ltd. (“ipa”) and ribopro, the potential for mrna-based antigen expression to enhance antibody discovery and development, and the ability of the partnership to accelerate the creation of novel immunotherapies. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024, (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas--(business wire)-- immunoprecise antibodies (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of kamil isaev to its board of directors and joseph scheffler as interim chief financial officer (cfo). additionally, ipa announces the planned departure of chris buyse from the board of directors. kamil isaev joins ipa’s board of directors ipa is pleased to welcome dr. isaev, a seasoned technology leader and venture strategist, to its board of directors. with over 30 years of expertise in ai, semiconductor technologies, and global r&d operations, isaev has held leadership roles at intel, dell emc, align technology, and abrt vc. his career has been defined by scaling r&d centers, driving ai-driven innovation, and leading high-impact cross-functional teams to bring emerging technologies to market. isaev currently serves as a venture partner at abrt vc, where he leads the abrt ai lab and the vc score project, developing ai-powered evaluation models to assess and rank ai startups, providing investors with data-driven insights to identify high-potential opportunities. his role at abrt vc is focused on bridging cutting-edge ai research with commercialization strategies, helping ai-driven companies refine their go-to-market approach and maximize scalability. previously, he held key leadership positions at intel corporation, where he served as director of developer relations engineering, overseeing global ai and software development teams and spearheading ai computing optimization, gpu workload migration, and machine learning integration. in this role, he worked closely with intel’s partners and customers to drive adoption and deployment of ai technologies in commercial and enterprise applications. before that, as country r&d general manager, he managed various software initiatives, ensuring efficient deployment of machine learning and deep learning solutions across intel's ecosystem, with a focus on operational efficiency and real-world implementation. beyond intel, isaev has led r&d and technology commercialization efforts at various organizations. at align technology, he managed a 600+ engineer r&d division, driving enterprise-wide digital transformation and agile adoption, while ensuring the successful transition of research initiatives into commercially viable products. as vice president of operations at caresyntax, he played a key role in the company’s u.s. expansion and the development of ai-driven surgical intelligence solutions, ensuring the integration of ai-driven insights into clinical workflows. at dell emc, he led solutions architecture for ai, healthcare, and video surveillance, focusing on bridging advanced technology development with industry adoption. isaev is also a member of ieee, a guest lecturer at leading universities, and a frequent speaker at ai and semiconductor industry conferences. he holds an msc and phd in physics (plasma physics and plasma chemistry) from moscow state university and has authored over 30 scientific publications in plasma physics and semiconductor technology. “we are delighted to welcome dr. isaev to our board,” said dr. jennifer bath, president and ceo. “his deep expertise in ai, r&d leadership, and commercialization of cutting-edge technology will be invaluable as we continue to expand our ai-driven biologics platform. kamil's proven track record in developing go-to-market strategies and his experience in bringing emerging technologies to commercial success aligns perfectly with our mission. his insights will be crucial as we navigate the complex landscape of ai in biologics and accelerate our path from innovation to market impact.” joseph scheffler appointed interim cfo ipa also announces the appointment of joseph scheffler as interim chief financial officer. scheffler is a highly experienced finance professional with over 20 years in public and multinational companies, specializing in financial reporting, forecasting, and business strategy. most recently, as interim corporate controller at nidec - kinetek, scheffler managed consolidated financial reporting for a $400 million global manufacturing firm with 40 subsidiaries worldwide. his background also includes extensive financial consulting for acquisitions and corporate strategy development, making him well-equipped to oversee ipa’s financial operations. “joseph brings a wealth of financial expertise and strategic insight,” said dr. jennifer bath. “his leadership will be instrumental in strengthening our financial strategy and supporting ipa’s continued growth.” scheffler holds an mba in finance and a bachelor’s in accounting from loyola university chicago, combining analytical expertise with strong stakeholder engagement. chris buyse departs board of directors ipa also announces that chris buyse has stepped down from the board of directors following his valuable tenure supporting the company during a transitional phase. “we are grateful to chris for his contributions and financial stewardship during this period of strategic evolution,” said dr. bath. “his expertise has been instrumental in ensuring continuity as we positioned the company for its next phase of growth. we wish him all the best in his future endeavors.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutic research and technology company specializing in ai-driven antibody discovery and development. through its subsidiaries—including talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v.—ipa delivers an end-to-end solution for the development of next-generation antibody therapeutics. the company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets. for more information, visit www.ipatherapeutics.com investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated contributions of kamil isaev as a member of the board of directors, the expected impact of joseph scheffler’s appointment as interim cfo, and the company’s continued strategic growth and execution of its ai-driven biologics initiatives. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to leadership transitions, technological advancements, regulatory developments, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should any of these risks materialize actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

rabbit b cell select ® drives clinical breakthroughs in cancer treatment victoria, british columbia--(business wire)-- immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using ipa’s proprietary b cell select ® platform for the clinical-stage company, oncoresponse inc. this achievement underscores ipa’s leadership as a contract research organization creating high-quality therapeutic antibodies, while pioneering work in the field of rabbit monoclonal antibody development. these antibodies are rapidly gaining recognition as a unique tool in therapies due to their distinctive properties, advancing into clinical trials aimed at improving patient outcomes. oncoresponse’s breakthrough in cancer treatment in a live presentation at the recent pegs 2024 conference, oncoresponse shared exciting updates on two novel antibodies, or502 and or641, both of which were discovered and refined using ipa’s innovative b cell select ® platform: or502, a novel, humanized anti-leukocyte immunoglobulin like receptor b2 (lilrb2) antibody, has successfully entered phase i/ii clinical trials, showing excellent safety profile, and is being evaluated for efficacy in treating advanced solid tumors. preclinical models have demonstrated that or502 is a best-in-class anti-lilrb2 antibody that reverses immunosuppression caused by myeloid cells in the tme. or641, a novel, humanized dual antagonist antibody targeting both lilrb1 and lilrb2, has completed cell line development and is undergoing ind-enabling studies. preclinical models have demonstrated its superior ability to reverse immunosuppression caused by myeloid and lymphoid cells compared to other anti-lilrb1/2 antibodies. driving antibody discovery and design for clinical success ipa’s proprietary b cell select ® platform has been instrumental in the rapid design and discovery of antibodies that have advanced to clinical stages for numerous clients. by preserving the natural structure of antibodies, ipa’s technology supports optimal functioning of the therapies in a clinical setting. through comprehensive testing and validation, the process ensures that these antibodies maintain their efficacy and reliability from the lab to the clinic. "at immunoprecise antibodies, our mission is not just to develop antibodies, but to redefine what’s possible in therapeutic interventions," said dr. jennifer bath, president and ceo of ipa. "our innovative platform, built on years of expertise, has consistently delivered antibodies with superior qualities, many of which are now advancing in clinical trials. this reflects our unwavering commitment to innovation and our strategic advantage in the market. we are proud to support our clients in bringing groundbreaking, life-changing treatments to patients around the world, reinforcing the long-term value of our technologies." harnessing rabbit b cell technology for breakthrough antibody discovery the rabbit b cell platform, a rapidly advancing technology in therapeutic antibody development, played a pivotal role in the discovery process. this platform excels at generating high-affinity and highly specific rabbit monoclonal antibodies, a demand met with very limited providers in the market. ipa has successfully utilized their b cell select platform in over 200 antibody programs, achieving remarkable success against a variety of targets, including small molecules, peptides, and proteins. the distinctive properties of rabbit antibodies, combined with ipa’s expertise, have consistently led to the development of promising therapeutic candidates. building on this success, ipa is now offering more complex therapeutic rabbit antibody campaigns as a partnering model, providing companies with greater flexibility in structuring their more complicated programs. outlook the field of rabbit monoclonal antibody (mab) therapeutics is advancing rapidly, driven by innovations in antibody engineering and humanization techniques. these advancements are making rabbit mabs increasingly popular for human therapeutic use. the unique properties of rabbit antibodies, combined with ipa’s full-service technologies, such as in silicohumanization, indicate a strong potential for more rabbit-derived mabs to enter clinical trials and achieve approval in the coming years. the distinctive advantages of rabbit antibodies make them a promising foundation for future therapeutic development. as this technology progresses, ipa remains at the forefront, harnessing these innovations to bring new, effective treatments to the clinic, reinforcing our growing leadership in the industry. dr. kamal d. puri, chief scientific officer of oncoresponse, recognized ipa’s pivotal role in their success, praising the quality and reliability of ipa’s antibody discovery services. “we are thrilled to have worked with ipa to discover our lead therapeutic antibodies. the ipa team’s deep experience and know-how with a battery of customized, high-throughput discovery strategies has played a critical role in the successful discovery of our molecules with unsurpassed speed and efficiency,” said kamal d. puri, chief scientific officer of oncoresponse. about or502 lilrb2 is an immunoinhibitory receptor expressed on tumor-associated macrophages (tams) found in the tumor microenvironment (tme). tams inhibit the activity of checkpoint inhibitor (cpi) therapy and prevent t cells from killing tumors. blocking the inhibitory activity of tams and promoting the activity of tumor-killing t cells reverses inhibition of cpi therapy, potentially leading to more and deeper responses to cpis in patients. this is the mechanism of or502, which modulates lilrb2 by blocking its engagement of hla-g on tumor cells and prevents the suppression of the myeloid cells. elevated expression of lilrb2 correlates with reduced patient survival in various tumor types. this humanized monoclonal antibody, or502, targets lilrb2 and blocks the inhibitory activity of tams and promotes the activity of tumor-killing t cells, reversing inhibition of cpi therapy. about oncoresponse oncoresponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. in a broad strategic alliance with md anderson cancer center, oncoresponse deploys a proprietary b-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment. the company’s lead clinical candidate, or502 is a best-in-class anti-lilrb2 antibody that rescues innate and adaptive immune responses from lilrb2-mediated immune suppression and has entered clinical study in 2023. or502 clinical studies are being conducted with support from the cancer prevention research institute of texas (cprit) dp230076. additional pipeline candidates that modulate suppressive macrophage activity are under development, including or641, a unique dual anti-lilrb2/1 antagonist antibody that promotes a th1-like immune response. for more information, please visit www.oncoresponse.com and follow us on linkedin and x. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). forward-looking statement this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, and clinical readiness or effectiveness of ipa-discovered therapeutics. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time, those assumptions include: the continued successful of ipa’s technology in discovering and developing antibodies, timely regulatory approval and acceptance of therapies developed using the company’s technologies, the potential for partnerships in antibody discovery and development; and the expectation that these technological advancements will drive increased revenue streams and sustained financial growth for the company. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com source: immunoprecise antibodies ltd.

victoria, british columbia--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, biostrand®, has published a preprint of its groundbreaking white paper titled, "new paradigm for biological sequence retrieval inspired by natural language processing and database research" on biorχiv. the publication delves into the intricacies of one of biostrand’s applications based on its patented hyft-based methodology, a novel and proprietary approach to biological sequence retrieval, and its clear advantages over the gold standard algorithm, basic local alignment search tool “blast”. by detailing their innovative approach and its potential implications for the scientific community, biostrand aims to foster collaboration and drive innovation in the realm of bioinformatics. key highlights from the white paper: introduction to hyft patterns: the paper introduces hyft patterns as unique signature sequences, akin to biological fingerprints, found in amino acids, dna, and rna. these patterns serve as a tool to tokenize and harmonize all biological data into a unified omics language. parsing and indexing with hyfts: the paper details the two-step process of parsing biological sequences to retrieve hyft patterns and then indexing them. this approach prioritizes non-overlapping hyfts with lower ranks, ensuring comprehensive coverage of the sequence. benchmarking results: a comparative study between blast and the hyft methodology revealed that while blast excels in retrieving distant homologous sequences, hyft is particularly relevant for higher identity matches. dirk van hyfte, md, phd, co-founder and head of innovation of biostrand, remarked, "the publication of our research on biorxiv.org is not just a milestone for biostrand, but a significant contribution to the bioinformatics community. we believe, given the ever-increasing availability of sequence data, our hyft-based sequence similarity search methodology offers the scalability needed in this era of big data without losing precision, and we eagerly anticipate the discourse and collaboration it will inspire." lensai: the next-generation advanced ai platform recently, biostrand successfully rolled out its next-generation unified knowledge graph-large language model (llm) framework for holistic life sciences research. at the core of their lensai platform is a comprehensive and continuously expanding knowledge graph that maps a remarkable 25 billion relationships across 660 million data objects, linking sequence, structure, function, and literature information from the entire biosphere. their first-in-class technology provides a comprehensive understanding of the relationships between genes, proteins, structures, and biological pathways, thereby opening powerful new opportunities for drug discovery and development. the platform leverages the latest advances in ontology-driven nlp and ai-driven llms to connect and correlate syntax (multi-modal sequential and structural data) and semantics (biological functions). biostrand’s unified approach to biomedical knowledge graphs, retrieval augmented generation (rag) models, and llms combines the reasoning capabilities of llms, the semantic proficiency of knowledge graphs, and the versatile information retrieval capabilities of rag, to streamline the integration, exploration, and analysis of biomedical data, potentially unlocking a realm of uncharted possibilities. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

the company to host an earnings conference call via webcast victoria, british columbia, june 29, 2023 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), a leader in ai-driven biotherapeutic research and technology, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and fiscal year end 2023, on friday, july 7, 2023, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. immunoprecise management will host the conference call followed by a question-and-answer period. conference call: event date: july 07, 2023 event time: 10:30 et participant details: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/109374701 about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com source: immunoprecise antibodies ltd.

dr. dirk van hyfte, head of innovation and co-founder at biostrand, stated, “the integration of hyft technology into our llms marks a transformative moment in biotechnology." see full announcement

company to present at the upcoming 2023 annual meeting of the american association for cancer research (aacr) immunoprecise’s unique proprietary bispecific antibodies link cells expressing tumor-associated antigen tropomyosin receptor kinase b (trkb) with cd3-positive t cells, immune system cells that respond by recognizing and eliminating cancer cells. the company’s potential therapeutic, which is designed to bring trkb-expressing tumor cells in contact with engaged and activated t cells, may represent a novel first-in-class therapeutic for targeting trkb-associated tumors in such cancers as non-small cell lung, breast, colon, head, neck, and pancreatic. studies show most tumors from these cancers express high levels of trkb1, and the protein’s presence is associated with poor prognosis and low survival rates. the company has filed a provisional patent application to the united state patent and trademark office. victoria, british colombia march 23, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, talem therapeutics, will present a scientific poster with their latest data on the development of bispecific t-cell engagers targeting trkb at the annual aacr meeting in orlando, florida, which is held from april 14 to 19, 2023. with this advanced development to target trkb-expressing tumor cells, ipa differentiates itself from other organizations developing immunotherapeutics to treat malignant solid tumors. the (over)expression of trkb and (over)activation of the trkb-signaling pathway play a crucial role in various malignancies and are associated with poor disease outcomes. currently applied pharmaceuticals target trkb through interference with its tyrosine kinase activity, but they lack specificity and are therefore associated with many adverse effects. at the 2023 annual aacr meeting, ipa will present their novel therapeutic design, exhibiting high specificity to the tumor-associated protein trkb, shown to be associated with cancer cell survival, proliferation, migration, and resistance to chemotherapy. the company will share data demonstrating the evidence for the potential therapeutic’s ability to recruit and activate t cells to target trkb-specific tumors, in what they believe may be a safer, more effective, and more targeted cancer therapy. the importance of the invention was appreciated in a provisional patent application filed by talem therapeutics to the united state patent and trademark office. dr. jennifer bath, ipa’s ceo and president, stated: “for years, we have consistently demonstrated success in creating clinically relevant therapies for our clients and partners by utilizing our advanced drug discovery and analytical capabilities. we take pride in revealing the details of a pioneering bispecific therapy that aims to revolutionize the approach to targeting and treating various solid tumors. our continuous goal is to create safer and more precise therapies, as we collaborate with our partners to develop the future generation of cancer treatment options.” the poster presentation “bispecific t cell engagers targeting trkb” ipa will exhibit their poster number 29 in section 25 on monday april 17th, from 9.00 am to 12.30 pm. the session category is ‘immunology’, and the session is entitled ‘therapeutic antibodies 1’. an abstract of the poster is presented under number 1890. 1. meng, l.; liu, b.; ji, r.; jiang, x.; yan, x.; xin, y. targeting the bdnf/trkb pathway for the treatment of tumors (review). oncol lett 2018. https://doi.org/10.3892/ol.2018.9854. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the safe activation of t cells, regarding therapeutic potential of ipa’s trkb x cd3 bispecific antibodies to treat trkb-related tumors, and the company’s ability to complete the development of their tatx-200 program. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

ipa’s project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary b cell select® platform and protein manufacturing services. talem therapeutics has announced a collaboration with libera bio to develop multi-target antibodies including the use of artificial intelligence (ai) technology. the companies will use talem's ai platform to help discover and optimize antibodies for various diseases, including cancer. this collaboration is expected to generate antibodies against disease targets that have historically been undruggable. briacell’s ai-based drug discovery program, after a brief pause due to additional workflows added, is underway and going well. the program is using biostrand’s lensai to analyze and prioritize potential drug targets for cancer treatment. briacell aims to use this technology to accelerate the development of new cancer therapies. biostrand announces the first monetization of its natural language processing (nlp) and immunogenicity modules. these modules are now allowing pharmaceutical companies to extract and analyze data from scientific publications and identify potential immunogenicity issues with drug candidates. biostrand is ramping its efforts to use this technology to help pharmaceutical companies develop safer and more effective drugs. biostrand's saas-based data management platform has been awarded a first-round rfp (request for proposal) by an undisclosed pharmaceutical company. the platform allows researchers to store, manage, and analyze large amounts of genomic, transcriptomic, and proteomic data using ai and hyfts technology. if awarded, this program is expected to help the pharmaceutical company accelerate its drug discovery process and improve its r&d efficiency. minimally, this third-party validation marks the beginning of a new potential revenue stream of great interest and high conceivable revenues for biostrand. victoria, british columbia (canada), march 16, 2023 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended january 31, 2023. “we are thrilled to announce that this quarter has been a foundational one for our company. our project revenue has experienced a significant increase, thanks to our recognized best-in-class platform of function-first b cell. in addition, our clients have shown a noticeable trend of moving away from transgenic animals, which may limit genetic diversity of outputs, and towards animals with diverse b cell repertoires and rapid, cost-effective next-generation humanization technologies – capabilities that ipa is again unique positioned to provide”, stated dr. jennifer bath, ceo of ipa. she added, “in addition to our established success, we have ventured into the promising field of modern artificial intelligence, expanding our revenue streams, and providing the first revenue for our subsidiary, biostrand. our newest, unique ai-powered research collaboration may also allow us to tackle previously undruggable targets within the cellular context, and we are excited about the unparalleled value proposition that this could offer our investors. we are equally excited about our ongoing efforts to finalize another ai-driven research collaboration for a complex oncology program with a leading global oncology therapeutics company. these strategic initiatives have been critical in driving growth, innovation, and shareholder value, and we remain confident in our ability to continue to deliver exceptional results. as a company, we are proud of our achievements, and we look forward to the continued success that these initiatives will bring.” third quarter fiscal year 2023 financial summary* (all comparisons are to the period ended january 31, 2022) ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, an increase of 7.4% compared to the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year. for the nine months ended january 31, 2023, total revenue growth of 10.9% when adjusting for the effect of currency translations. gross profit increased 14.6% to $3.0 million for the three months ended january 31, 2023 as compared to the same period last year. ipa held cash of $11.4 million as of january 31, 2023. *expressed in canadian dollars, unless otherwise indicated. financial results revenue & gross profit ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, a 7.4% increase from the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year, driven by growth in the company’s b cell select® platform and protein manufacturing services. gross profit increased 14.6% to $3.0 million from the same period last year. liquidity and capital resources as of january 31, 2023, ipa held $11.4 million of cash, as compared to $30.0 million as of april 30, 2022, and had working capital of $12.2 million. ipa does not hold cash at silicon valley bank and has not seen any impact on our business from the collapse and subsequent take-over of the bank. polytope® taxt-03 antibody combination therapy talem, ipa's subsidiary, has experienced unanticipated delays in the production of its anti-covid therapeutic drug product, polytope, and has adjusted its milestones accordingly, having yet to receive the drug product from its cdmo partner, chempartner. talem is working closely with chempartner to negotiate a mutually beneficial outcome. due to these circumstances, the decision has been made to significantly reduce further investment in talem's covid program, while still recognizing the ongoing significance of covid-19 globally. ipa will continue to provide updates on talem's progress with chempartner and appreciates the support and patience of its investors during these discussions. conference call: date: thursday, march 16, 2023 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/683815668 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

the program will leverage biostrand’s lensai® full suite of integrated intelligence technology® with libera bio’s multifunctional polymeric nanocapsules (mpn technology®) the alliance has stipulated a minimum of upfront and downstream milestone payments of usd 155 million plus commercial royalties, per product developed victoria, canada and santiago de compostela, spain, march 15, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that talem therapeutics llc, an independently operating subsidiary of ipa, and libera bio s.l., have signed a collaboration agreement to jointly address intracellular targets. it is estimated that 75% of disease-causing targets are located inside cells1. some of the most elusive cancer targets are expressed inside tumor cells. because they are so difficult to address, they have sometimes been deemed “undruggable” and thus represent high unmet medical needs. numerous pathways intersect inside tumor cells, such as the mapk pathway or the “hedgehog pathway”, and may generate conditions for tumors to develop, grow and evade the immune system. disrupting signals at one or more points within these pathways may slow down the growth of the tumors and inhibit their proliferation. small molecules have been successfully developed to this end, but they often present a significant lack of specificity resulting in toxicity, leading to undesirable side effects for patients. engineering antibodies to force them inside tumor cells has also been attempted, but it is a complex process, often wrought with failure. the collaboration between talem and libera bio will leverage a nanotechnology that has been proven in vivo to deliver antibodies inside tumor cells and provides a potential solution to this medical challenge. libera bio’s multifunctional polymeric nanocapsules (mpn technology®) offer an elegant way to deliver antibodies inside tumor cells. the relevant antibodies are encapsulated in multi-layer nanocapsules of approximately 1/10,000th of a millimeter in diameter. the nanocapsules are specifically designed around the physicochemical properties of antibodies, to protect them from degradation in the blood stream. libera bio believes that this might be the only nanotechnology with in vivo proof of concept of delivering whole antibodies intracellularly. in addition, mpns can deliver other biologic modalities or combinations of a biologic and a small molecule in the same nanocapsule. passively or actively targeted, the mpns deliver these compounds through a cell membrane and to intracellular targets. whole antibodies, close to their natural form, can be delivered in this manner. talem will leverage its antibody discovery and development expertise and access, including without limitation, the lensai technology® from biostrand b.v., an independently operating subsidiary of ipa. biostrand has developed a proprietary, ai-driven platform to optimize the design of such antibodies. biostrand computationally generates and rapidly screens a large set of diverse antibody candidates against a prioritized list of targets, including intracellular targets. talem and libera bio will jointly develop novel antibodies for use with mpn delivery, with the goal of offering them to larger pharma companies to conduct late-stage development and commercialization. the work launches with the investigation of two intracellular targets with very high unmet patient needs to offer options to the oncologists treating them. “as we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the 'holy grail' in oncology. libera bio's ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously 'undruggable' targets is an exciting development that has the potential to transform the way we treat cancer,” said dr. jennifer bath, ceo and president of immunoprecise antibodies ltd. “the libera bio team has been very impressed with the combination of modern in silico tools and wet lab capabilities at the ipa family of companies. we are looking forward to this alliance that just may yield dozens of new options for cancer treatment,” added olivier jarry, co-founder and ceo of libera bio. 1. verdine gl, walensky ld. the challenge of drugging undruggable targets in cancer: lessons learned from targeting bcl-2 family members. clin cancer res. 2007;13(24):7264-70. doi:10.1158/1078-0432.ccr-07-2184. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com about libera bio. s.l. libera bio s.l. (www.liberabio.com) is a private spanish company, spun off from the university of santiago de compostela (galicia, spain). libera bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “holy grail” in oncology. it has conducted preclinical studies of antibodies addressing frequent mutations of kras, a protein involved in a large number of cancers, particularly pancreatic, colorectal and lung cancers. it is now preparing for the enabling studies aiming at a clinical trial authorization. visit http://liberabio.com contact: olivier jarry, ceo, contact@liberabio.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, british columbia (canada), august 29, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), a biotherapeutic research and technology company, today announced the… lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet.

the company to host an earnings conference call via webcast victoria, british columbia (canada), july 26, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa)… lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet.